Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014 Feb;32(1):167–203. doi: https://doi.org/10.1016/j.emc.2013.09.002.

Article  PubMed  Google Scholar 

Torrisi M J, Schwartz L H, Gollub M J, Bosl G J, Hricak H. CT Findings of Chemotherapy-induced Toxicity: What Radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology: Volume 258: Number 1—January 2011 doi:https://doi.org/10.1148/radiol.10092129/-/DC1.

Viswanathan C, Truong M T, Sagebiel T L, Bronstein Y, Vikram R, Patnana M, Silverman P M, Bhosale P R. Abdominal and Pelvic complications of nonoperative oncologic therapy. RadioGraphics 2014; 34:941–961 doi:https://doi.org/10.1148/rg.344140082.

Article  PubMed  Google Scholar 

Lewis A, Chaft J, Girotra M, Fisher G W. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 124 (3): 251e260 (2020) https://doi.org/10.1016/j.bja.2019.11.034.

Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6): 559–568.

CAS  PubMed  Article  Google Scholar 

Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008; 19(3):577–582.

CAS  PubMed  Article  Google Scholar 

Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14(2):135–141.

PubMed  Article  Google Scholar 

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995–2025.

PubMed  Article  Google Scholar 

Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632–639.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997; 4:385–389.

Article  Google Scholar 

Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 2006;33:106–20.

CAS  PubMed  Article  Google Scholar 

Inrhaoun H, Kullman T, Elghissassi I, et al. Treatment of chemotherapy-induced nausea and vomiting. J Gastrointest Cancer 2012;43:541–6.

CAS  PubMed  Article  Google Scholar 

Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007;13:181–98.

CAS  PubMed  Article  Google Scholar 

Gibson RJ, Stringer AM. Chemotherapy-induced diarrhea. Curr Opin Support Palliat Care 2009;3:31–5.

PubMed  Article  Google Scholar 

Saliba F, Hagipantelli R, Misset J, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 1998 Aug; 16(8):2745–51

CAS  PubMed  Article  Google Scholar 

Siber GR, Mayer RJ and Levin MJ. Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. Cancer Res. 1980 Oct; 40(10):3430–6

CAS  PubMed  Google Scholar 

Rosenberg RF, Caridi JG. Vincristine-induced megacolon. Gastrointest Radiol 1983; 8(1):71–73.

CAS  PubMed  Article  Google Scholar 

Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000;355:281–3

CAS  PubMed  Article  Google Scholar 

Hussein MA, Bird BR, O’Sullivan MJ, et al. Symptoms in cancer patients and an unusual tumor: Case 2. Docetaxel-related ischemic colitis. J Clin Oncol 2005; 23:9424–5.

PubMed  Article  Google Scholar 

Han E S, Monk B J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecologic Oncology 105 (2007) 3–6.

CAS  PubMed  Article  Google Scholar 

Wiesner W, Mortelé KJ, Glickman JN, Ji H, Ros PR. Pneumatosis intestinalis and portomesenteric venous gas in intestinal ischemia: correlation of CT findings with severity of ischemia and clinical outcome. AJR Am J Roentgenol 2001;177(6): 1319–1323.

Kung D, Ruan DT, Chan RK, Ericsson ML, Saund MS. Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin. Dig Dis Sci 2008;53(1):217–219.

PubMed  Article  Google Scholar 

Schulze CG, Blum U, Haag K. Hepatic portal venous gas: imaging modalities and clinical significance. Acta Radiol 1995;36:377–380

CAS  PubMed  Article  Google Scholar 

Harandi A, Zaidi A S, Stocker A M, Laber D A. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009; 2009:567486.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Thoeni RF, Cello JP. CT imaging of colitis. Radiology 2006;240(3):623–638.

PubMed  Article  Google Scholar 

Asnacios A, Naveau S, Perlemuter G. Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer 2009;45(suppl 1): 332–342.

PubMed  Article  Google Scholar 

Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases. 2019 Feb 26; 7(4): 405–418.

PubMed  PubMed Central  Article  Google Scholar 

Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12(12):1443–1455.

CAS  PubMed  Article  Google Scholar 

Gonzalez-Cao M, Boada A, Teixidó C, Fernandez-Figueras M T, Mayo C, Tresserra F, Bustamante J, Viteri S, Puertas E, Santarpia MC, Riso A, Barron F, Karachaliou N and Rosell R. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. Oncotarget. 2016 Aug 30; 7(35): 56619–56627 doi: https://doi.org/10.18632/oncotarget.10651

Article  PubMed  PubMed Central  Google Scholar 

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3 open-label randomised trial. Lancet Oncol. 2015;16:1389–98.

CAS  PubMed  Article  Google Scholar 

Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009;22(1):115–128.

CAS  PubMed  Article  Google Scholar 

Calabro’ L. Di Giacomo A.M., et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? Journal of Experimental and Clinical Cancer Research March 2007

Gupta A, Long JB, Chen J, Gross CP, Feldman DR, Steingart RM. Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. J Urol. 2016 Jan; 195(1):33–40. doi: https://doi.org/10.1016/j.juro.2015.08.088.

CAS  Article  PubMed  Google Scholar 

Dasanu C A. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin. Drug Saf. (2008) 7(6)

Zecchina G, Ghio P, Bosio S et al. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007;8:264–7

CAS  PubMed  Article  Google Scholar 

Kuenen BC, Levi M, Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21:2192–8

CAS  PubMed  Article  Google Scholar 

Guerrini S, Bucalossi A, Cioffi Squitieri N, Mazzei FG, Volterrani L, Mazzei MA. Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma. Tumori. 2016 Nov 11;102(Suppl. 2). doi: https://doi.org/10.5301/tj.5000392.

Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296(21):2558–2560.

CAS  PubMed  Article  Google Scholar 

Grassi R, Rambaldi PF, Di Grezia G, et al. Inflammatory bowel disease: Value in diagnosis and management of MDCT-enteroclysis and 99mTc-HMPAO labeled leukocyte scintigraphy. Abdom Radiol 2011;36(4): 372–381.

Google Scholar 

Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42(18):3127–3139.

CAS  PubMed  Article  Google Scholar 

Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018 Jun;23(3):410–420. doi: https://doi.org/10.1007/s10147-018-1259-6

CAS  Article  PubMed  Google Scholar 

Tsukamoto J, Monteiro M, Vale S, Lemos C, Scarpelli T, Carvalho L, Pezzutti D, Brandao R. Thromboembolic events related to treatment with checkpoint inhibitors: report of two cases. Case Rep Oncol. 2018 Sep-Dec; 11(3): 648–653. doi: https://doi.org/10.1159/000492463

Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R. Rare, but Severe: Vasculitis and Checkpoint Inhibitors. Eur Urol Focus. 2019 May 6. doi: https://doi.org/10.1016/j.euf.2019.04.014.

Article  PubMed  Google Scholar 

Petrioli R, Mazzei MA, et al Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study. Anti-Cancer Drugs 2020.

Terlouw LG, Moelker A, Abrahamsen J, et al. European guidelines on chronic mesenteric ischaemia-Joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study Group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. United European Gastroenterol J. 2020;8(4):371–395. doi:https://doi.org/10.1177/2050640620916681

Article  PubMed  PubMed Central  Google Scholar 

Somma F, Faggian A, Serra N, et al. Bowel intussusceptions in adults: the role of imaging. Radiol Med 2014;120(1): 105–117

PubMed  Article  Google Scholar 

Berritto D, Iacobellis F, Mazzei MA, Volterrani L, Guglielmi G, Brunese L, Grassi R. MDCT in ischaemic colitis: how to define the aetiology and acute, subacute and chronic phase of damage in the emergency setting. Br J Radiol. 2016;89(1061):20150821. doi: https://doi.org/10.1259/bjr.20150821).

Article